<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886597</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-OLI-2016-23</org_study_id>
    <nct_id>NCT03886597</nct_id>
  </id_info>
  <brief_title>Nutritional Intervention With Table Olives in Healthy Volunteers</brief_title>
  <acronym>BIOLIVA</acronym>
  <official_title>Table Olives Nutritional Intervention: Pharmacokinetics of Polyphenols and Pentacyclic Triterpenes and Assessment of Antioxidant, Cardiovascular and Anti-inflammatory Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Economía y Competitividad (Spain) AGL 2013-41188R</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Olives and olive oil are typical components of the Mediterranean diet being part of its
      cultural and gastronomic heritage. Since ancient times, olives have been used either for
      both, oil extraction or whole fruit consumption as table olives. Olive oil stands out from
      both the nutritional and the health point of view. However, the effect of table olives
      consumption remains almost unknown. The beneficial properties of olive oil have been
      initially ascribed to the high concentration of oleic acid. Nowadays, these positive effects
      have been attributed also to minor compounds such as polyphenols or pentacyclic triterpenes.
      Table olives contain a higher amount of both polyphenols and pentacyclic triterpenes than
      their oil, with the same healthy fatty acid profile. Therefore, the present intervention aims
      at investigating the pharmacokinetic of polyphenols and pentacyclic triterpenes after a
      single olive intake as well as the assessment of the effect of the consumption of olives
      during 30 days on the overall health status playing particular attention to the
      anti-inflammatory, antioxidant and cardiovascular biomarkers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Actual">June 15, 2019</completion_date>
  <primary_completion_date type="Actual">May 25, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study involve two stages, the first one corresponding to the pharmacokinetic study of the single administration of table olives in healthy male volunteers and the second one corresponding to the study of a nutritional intervention with 30 table olives during 30 days.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stage 1: Maximum plasma concentration (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Concentration at the end of the dosing interval (Ct)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Time until Cmax is reached (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Area under the curve from administration to last observed concentration at time (AUC (0-t)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: AUC extrapolated to infinite time (AUC (0-∞)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Percentage of AUC extrapolated (AUC%)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Terminal elimination rate constant (Kel)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Plasma concentration half-life (t ½)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Volume of distribution (Vd/ F)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Clearance (Cl/F)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Peak trough fluctuation over one dosing interval at steady state (PTF)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Cmax dose normalized (Cmax/Dose)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: AUC (0-t) dose normalized (AUC (0-t)/Dose)</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Urine polyphenols concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 1: Urine triterpenes concentration</measure>
    <time_frame>24 hours</time_frame>
    <description>24 hour dosing period; 2 dosing periods each separated by 7 days washout</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Plasma polyphenols concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Plasma triterpenes concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Urine polyphenols concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Urine triterpenes concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Malondialdehyde concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Catalase concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Glutathione peroxidase concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Superoxide dismutase concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: F2A isoprostane concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: 8 isoprostane concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Oxidized low-density lipoprotein concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: C-Reactive Protein concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Lipoprotein-associated phospholipase A2 concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Apolipoprotein A1 concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Apolipoprotein B100 concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Tumor necrosis factor alpha concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Interleukin 6 concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stage 2: Interleukin 1 concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stage 1 and 2: Number of participants with treatment-related adverse events</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 and 2: Systolic and diastolic blood pressure</measure>
    <time_frame>Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>Stage 1: 24 hours, Stage 2: 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 and 2: Heart rate</measure>
    <time_frame>Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>Stage 1: 24 hours, Stage 2: 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 1 and 2: Respiratory rate</measure>
    <time_frame>Stage 1: 24 hour dosing period; 2 dosing periods each separated by 7 days washout, Stage 2: 30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>Stage 1: 24 hours, Stage 2: 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Body weight</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: High-density lipoprotein cholesterol concentration (HDL-C)</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Low-density lipoprotein cholesterol concentration (LDL-C)</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Very low-density lipoprotein cholesterol concentration (VLDL-C)</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Triglyceride concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Total cholesterol concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Sodium concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Glucose concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Urea concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Creatinine concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Aspartate aminotransferase concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Alanine aminotransferase concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Alkaline phosphatase concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stage 2: Total proteins concentration</measure>
    <time_frame>30 days dosing period or 30 days as control group separated by 15 days washout</time_frame>
    <description>30 days</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy</condition>
  <condition>Biological Availability</condition>
  <condition>Nutritional Intervention</condition>
  <condition>Functional Food</condition>
  <condition>Nutrition Physiology</condition>
  <arm_group>
    <arm_group_label>60 Arbequina Table Olives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetics Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 Arbequina Table Olives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pharmacokinetics Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 Table Olives</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Table Olives Nutritional Intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control of Table Olives Nutritional Intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Table Olives</intervention_name>
    <description>At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 60 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 5 minutes to ingest 60 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.</description>
    <arm_group_label>60 Arbequina Table Olives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Table Olives</intervention_name>
    <description>At early morning (08:00 h e.g.) and after 10 hours of fasting conditions, the olives of the Arbequina variety will be administered to each subject. The 120 olives will be weighted before the ingestion and the remaining stones will be subsequently weighted to keep a record of the amount of olive pulp that has been consumed. The subjects will have a period of 10 minutes to ingest 120 olives with 240 mL of water. Blood samples will be collected from 1 hour prior to administration until 24 hours after dosing. Urine samples will also be collected and blood pressure will be measured.</description>
    <arm_group_label>120 Arbequina Table Olives</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Table Olives</intervention_name>
    <description>All the subjects will perform two experimental sessions of 30 days with 15 days of washout periods within experimental periods. In one experimental session subjects will ingest table olives and in the other session they will act as their own controls following their normal dietary habits. During all the experiment participants will avoid the consumption of products rich in phenolic and triterpenic compounds. Subjects will include the dose of 60 table olives within their normal dietary habits. Consequently, the olives will be consumed two times daily within each main meal; 30 olives before lunch and 30 olives before dinner. Blood samples will be collected at baseline and 15 and 30 days of each experimental session. Tolerability variables and blood pressure will also be measured.</description>
    <arm_group_label>60 Table Olives</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index between 19 and 30 kg/m2.

          -  Healthy on the basis of physical examination and routine biochemical and hematological
             laboratory determinations.

          -  Free acceptance to participate in the study by obtains signed informed consent.

        Exclusion Criteria:

          -  Smoking.

          -  Alcohol or drug abuse.

          -  Heavy consumer of stimulating beverages (&gt;5 coffees, teas, chocolate or cola drinks
             per day) and grapefruit juice.

          -  Background of allergy, idiosyncrasy or hypersensitivity to drugs.

          -  Intake of any medication within 2 weeks prior taking the study intervention (except
             for use of paracetamol in short-term symptomatic treatments), including
             over-the-counter products (including natural food supplements, vitamins and medicinal
             plants products), or any enzymatic inductor or inhibitor within 3 months before the
             drug administration.

          -  Positive serology for hepatitis B, C or HIV.

          -  Background or clinical evidence of cardiovascular, respiratory, renal, hepatic,
             endocrine, gastrointestinal, hematological or neurological disease or other chronic
             diseases.

          -  Having undergone major surgery during the previous 6 months.

          -  Pregnancy or lactation status (if applied).

          -  Participation in another clinical trial during the 3 months preceding the drug
             administration.

          -  Donation of blood during the 4 weeks preceding the drug administration.

          -  Acute illness four weeks before drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joana M Planas, PhD Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Departament de Bioquímica i Fisiologia. Facultat de Farmàcia i Ciències de l´Alimentació. Universitat de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Recerca Hospital de la Santa Creu i Sant Pau - CIM Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bachhav SS, Bhutada MS, Patil SP, Sharma KS, Patil SD. Oleanolic Acid Prevents Increase in Blood Pressure and Nephrotoxicity in Nitric Oxide Dependent Type of Hypertension in Rats. Pharmacognosy Res. 2014 Oct-Dec;7(4):385-92. doi: 10.4103/0974-8490.159575.</citation>
    <PMID>26692754</PMID>
  </reference>
  <reference>
    <citation>Cicerale S, Conlan XA, Sinclair AJ, Keast RS. Chemistry and health of olive oil phenolics. Crit Rev Food Sci Nutr. 2009 Mar;49(3):218-36. doi: 10.1080/10408390701856223. Review.</citation>
    <PMID>19093267</PMID>
  </reference>
  <reference>
    <citation>Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 Sep 5;145(5):333-41.</citation>
    <PMID>16954359</PMID>
  </reference>
  <reference>
    <citation>de la Torre-Carbot K, Chávez-Servín JL, Jaúregui O, Castellote AI, Lamuela-Raventós RM, Fitó M, Covas MI, Muñoz-Aguayo D, López-Sabater MC. Presence of virgin olive oil phenolic metabolites in human low density lipoprotein fraction: determination by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Anal Chim Acta. 2007 Feb 5;583(2):402-10. Epub 2006 Nov 2.</citation>
    <PMID>17386573</PMID>
  </reference>
  <reference>
    <citation>Dzubak P, Hajduch M, Vydra D, Hustova A, Kvasnica M, Biedermann D, Markova L, Urban M, Sarek J. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep. 2006 Jun;23(3):394-411. Epub 2006 May 3. Review.</citation>
    <PMID>16741586</PMID>
  </reference>
  <reference>
    <citation>Ghanbari R, Anwar F, Alkharfy KM, Gilani AH, Saari N. Valuable nutrients and functional bioactives in different parts of olive (Olea europaea L.)-a review. Int J Mol Sci. 2012;13(3):3291-340. doi: 10.3390/ijms13033291. Epub 2012 Mar 12. Review.</citation>
    <PMID>22489153</PMID>
  </reference>
  <reference>
    <citation>Juan ME, Planas JM, Ruiz-Gutierrez V, Daniel H, Wenzel U. Antiproliferative and apoptosis-inducing effects of maslinic and oleanolic acids, two pentacyclic triterpenes from olives, on HT-29 colon cancer cells. Br J Nutr. 2008 Jul;100(1):36-43. doi: 10.1017/S0007114508882979. Epub 2008 Feb 26.</citation>
    <PMID>18298868</PMID>
  </reference>
  <reference>
    <citation>Kountouri AM, Mylona A, Kaliora AC, Andrikopoulos NK. Bioavailability of the phenolic compounds of the fruits (drupes) of Olea europaea (olives): impact on plasma antioxidant status in humans. Phytomedicine. 2007 Oct;14(10):659-67. Epub 2007 Sep 17.</citation>
    <PMID>17870451</PMID>
  </reference>
  <reference>
    <citation>Liu J, Sun H, Duan W, Mu D, Zhang L. Maslinic acid reduces blood glucose in KK-Ay mice. Biol Pharm Bull. 2007 Nov;30(11):2075-8.</citation>
    <PMID>17978478</PMID>
  </reference>
  <reference>
    <citation>Lou-Bonafonte JM, Arnal C, Navarro MA, Osada J. Efficacy of bioactive compounds from extra virgin olive oil to modulate atherosclerosis development. Mol Nutr Food Res. 2012 Jul;56(7):1043-57. doi: 10.1002/mnfr.201100668. Review.</citation>
    <PMID>22760979</PMID>
  </reference>
  <reference>
    <citation>Lozano-Mena G, Sánchez-González M, Juan ME, Planas JM. Maslinic acid, a natural phytoalexin-type triterpene from olives--a promising nutraceutical? Molecules. 2014 Aug 4;19(8):11538-59. doi: 10.3390/molecules190811538. Review.</citation>
    <PMID>25093990</PMID>
  </reference>
  <reference>
    <citation>Madlala HP, Van Heerden FR, Mubagwa K, Musabayane CT. Changes in Renal Function and Oxidative Status Associated with the Hypotensive Effects of Oleanolic Acid and Related Synthetic Derivatives in Experimental Animals. PLoS One. 2015 Jun 5;10(6):e0128192. doi: 10.1371/journal.pone.0128192. eCollection 2015.</citation>
    <PMID>26046776</PMID>
  </reference>
  <reference>
    <citation>Marrugat J, Covas MI, Fitó M, Schröder H, Miró-Casas E, Gimeno E, López-Sabater MC, de la Torre R, Farré M; SOLOS Investigators. Effects of differing phenolic content in dietary olive oils on lipids and LDL oxidation--a randomized controlled trial. Eur J Nutr. 2004 Jun;43(3):140-7. Epub 2004 Jan 6.</citation>
    <PMID>15168036</PMID>
  </reference>
  <reference>
    <citation>Martín-Peláez S, Covas MI, Fitó M, Kušar A, Pravst I. Health effects of olive oil polyphenols: recent advances and possibilities for the use of health claims. Mol Nutr Food Res. 2013 May;57(5):760-71. doi: 10.1002/mnfr.201200421. Epub 2013 Mar 1. Review.</citation>
    <PMID>23450515</PMID>
  </reference>
  <reference>
    <citation>Melliou E, Zweigenbaum JA, Mitchell AE. Ultrahigh-pressure liquid chromatography triple-quadrupole tandem mass spectrometry quantitation of polyphenols and secoiridoids in california-style black ripe olives and dry salt-cured olives. J Agric Food Chem. 2015 Mar 11;63(9):2400-5. doi: 10.1021/jf506367e. Epub 2015 Feb 26.</citation>
    <PMID>25668132</PMID>
  </reference>
  <reference>
    <citation>Poudyal H, Campbell F, Brown L. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr. 2010 May;140(5):946-53. doi: 10.3945/jn.109.117812. Epub 2010 Mar 24.</citation>
    <PMID>20335636</PMID>
  </reference>
  <reference>
    <citation>Rodriguez-Rodriguez R, Perona JS, Herrera MD, Ruiz-Gutierrez V. Triterpenic compounds from &quot;orujo&quot; olive oil elicit vasorelaxation in aorta from spontaneously hypertensive rats. J Agric Food Chem. 2006 Mar 22;54(6):2096-102.</citation>
    <PMID>16536581</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Quesada C, López-Biedma A, Warleta F, Campos M, Beltrán G, Gaforio JJ. Bioactive properties of the main triterpenes found in olives, virgin olive oil, and leaves of Olea europaea. J Agric Food Chem. 2013 Dec 18;61(50):12173-82. doi: 10.1021/jf403154e. Epub 2013 Nov 22. Review.</citation>
    <PMID>24279741</PMID>
  </reference>
  <reference>
    <citation>Uylaşer V, Yildiz G. The historical development and nutritional importance of olive and olive oil constituted an important part of the Mediterranean diet. Crit Rev Food Sci Nutr. 2014;54(8):1092-101. doi: 10.1080/10408398.2011.626874.</citation>
    <PMID>24499124</PMID>
  </reference>
  <reference>
    <citation>Weinbrenner T, Fitó M, de la Torre R, Saez GT, Rijken P, Tormos C, Coolen S, Albaladejo MF, Abanades S, Schroder H, Marrugat J, Covas MI. Olive oils high in phenolic compounds modulate oxidative/antioxidative status in men. J Nutr. 2004 Sep;134(9):2314-21.</citation>
    <PMID>15333722</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 15, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polyphenols</keyword>
  <keyword>Triterpenes</keyword>
  <keyword>Olea europaea</keyword>
  <keyword>Table Olives</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Functional Food</keyword>
  <keyword>Antioxidant</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Anti-inflammatory</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

